Relapse in acute myeloid leukaemia is driven by malignant cells that resist standard treatment. A synthetic cytokine approach in development targets inflammatory cell death pathways to suppress leukaemic cells while preserving healthy haematopoiesis.

Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.

ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for its inaugural Cell and Gene Therapy 2026 conference, taking place at Hinxton Hall in Cambridge from 9–10 March.

A newly developed AI-driven technique could dramatically speed up the discovery of drugs and advanced materials, enabling scientists to design chemically valid, property-targeted molecules in minutes rather than years.

Researchers have discovered how seemingly supportive brain cells help glioblastoma thrive, whilst identifying an existing HIV drug, Maraviroc, that could be repurposed to slow tumour growth.

New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.

Biotech company, Tubulis, has published preclinical data on its Alco5 antibody-drug conjugate platform, demonstrating the ability to link antibodies with previously inaccessible hydroxy-containing drugs.

Researchers have developed virus-inspired LENN nanoparticles that deliver mRNA therapies directly to bladder cancer cells, remain stable after freeze-drying and avoid triggering immune responses.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.

Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.